VISEN PHARMA-B Reports No Share Movements for August 2026; Public Float Remains Adequate

Bulletin Express09-01

VISEN PHARMA-B (VISEN Pharmaceuticals) filed its monthly return for the period ended 31 August 2026, confirming a stable capital structure and compliance with Hong Kong Stock Exchange public-float requirements.

Authorised Capital • Authorised share count remained at 500.00 million ordinary shares with a par value of USD 0.0001, keeping total authorised capital unchanged at USD 50,000.

Issued and Treasury Shares • Outstanding shares (excluding treasury) stood at 113.75 million, while treasury shares were 173,500, leaving total issued shares at 113.93 million. • No shares were issued, cancelled, repurchased, or transferred during the month, resulting in zero change to both issued and treasury share balances.

Public Float • The company confirmed compliance with the Main Board’s minimum 25% public-float threshold as at 31 August 2026.

Equity Incentive Schemes • Post-IPO Share Award Scheme (adopted 16 November 2022) recorded no share issuances or treasury transfers in August. • The scheme’s current mandate allows up to 2.40 million shares to be issued upon vesting; historical grants comprise 435,000 shares in June 2025 and 514,068 shares in July 2026.

Regulatory Confirmation • The filing attests that any past share issuances have been duly authorised, funds received, and all Hong Kong listing rule conditions satisfied.

Overall, VISEN PHARMA-B maintained a static share capital base in August 2026 with sufficient public float, signalling capital stability ahead of future vesting events under its share award programme.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171112454?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 17:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171112454","market":"us","top_or_hot":-1,"title":"VISEN PHARMA-B Reports No Share Movements for August 2026; Public Float Remains Adequate","media":"Bulletin Express","content":"<p>VISEN PHARMA-B (VISEN Pharmaceuticals) filed its monthly return for the period ended 31 August 2026, confirming a stable capital structure and compliance with Hong Kong Stock Exchange public-float requirements.</p>\n<p>Authorised Capital  \n• Authorised share count remained at 500.00 million ordinary shares with a par value of USD 0.0001, keeping total authorised capital unchanged at USD 50,000.</p>\n<p>Issued and Treasury Shares  \n• Outstanding shares (excluding treasury) stood at 113.75 million, while treasury shares were 173,500, leaving total issued shares at 113.93 million.  \n• No shares were issued, cancelled, repurchased, or transferred during the month, resulting in zero change to both issued and treasury share balances.</p>\n<p>Public Float  \n• The company confirmed compliance with the Main Board’s minimum 25% public-float threshold as at 31 August 2026.</p>\n<p>Equity Incentive Schemes  \n• Post-IPO Share Award Scheme (adopted 16 November 2022) recorded no share issuances or treasury transfers in August.  \n• The scheme’s current mandate allows up to 2.40 million shares to be issued upon vesting; historical grants comprise 435,000 shares in June 2025 and 514,068 shares in July 2026.</p>\n<p>Regulatory Confirmation  \n• The filing attests that any past share issuances have been duly authorised, funds received, and all Hong Kong listing rule conditions satisfied.</p>\n<p>Overall, VISEN PHARMA-B maintained a static share capital base in August 2026 with sufficient public float, signalling capital stability ahead of future vesting events under its share award programme.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN PHARMA-B Reports No Share Movements for August 2026; Public Float Remains Adequate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN PHARMA-B Reports No Share Movements for August 2026; Public Float Remains Adequate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-01 17:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN PHARMA-B (VISEN Pharmaceuticals) filed its monthly return for the period ended 31 August 2026, confirming a stable capital structure and compliance with Hong Kong Stock Exchange public-float requirements.</p>\n<p>Authorised Capital  \n• Authorised share count remained at 500.00 million ordinary shares with a par value of USD 0.0001, keeping total authorised capital unchanged at USD 50,000.</p>\n<p>Issued and Treasury Shares  \n• Outstanding shares (excluding treasury) stood at 113.75 million, while treasury shares were 173,500, leaving total issued shares at 113.93 million.  \n• No shares were issued, cancelled, repurchased, or transferred during the month, resulting in zero change to both issued and treasury share balances.</p>\n<p>Public Float  \n• The company confirmed compliance with the Main Board’s minimum 25% public-float threshold as at 31 August 2026.</p>\n<p>Equity Incentive Schemes  \n• Post-IPO Share Award Scheme (adopted 16 November 2022) recorded no share issuances or treasury transfers in August.  \n• The scheme’s current mandate allows up to 2.40 million shares to be issued upon vesting; historical grants comprise 435,000 shares in June 2025 and 514,068 shares in July 2026.</p>\n<p>Regulatory Confirmation  \n• The filing attests that any past share issuances have been duly authorised, funds received, and all Hong Kong listing rule conditions satisfied.</p>\n<p>Overall, VISEN PHARMA-B maintained a static share capital base in August 2026 with sufficient public float, signalling capital stability ahead of future vesting events under its share award programme.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维升药业-B","start_time":0,"source_url":"","article_id":"1171112454","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171112454","pubTimestamp":1788255018,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN PHARMA-B (VISEN Pharmaceuticals) filed its monthly return for the period ended 31 August 2026, confirming a stable capital structure and compliance with Hong Kong Stock Exchange public-float...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维升药业-B"},"translate_title":"VISEN PHARMA-B 报告 2026 年 8 月没有股价变动；公众持股量仍然充足","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN PHARMA-B (VISEN Pharmaceuticals) filed its monthly return for the period ended 31 August 2026, confirming a stable capital structure and compliance with Hong Kong Stock Exchange public-float requirements.\nAuthorised Capital  \n• Authorised share count remained at 500.00 million ordinary shares with a par value of USD 0.0001, keeping total authorised capital unchanged at USD 50,000.\nIssued and Treasury Shares  \n• Outstanding shares (excluding treasury) stood at 113.75 million, while treasury shares were 173,500, leaving total issued shares at 113.93 million.  \n• No shares were issued, cancelled, repurchased, or transferred during the month, resulting in zero change to both issued and treasury share balances.\nPublic Float  \n• The company confirmed compliance with the Main Board’s minimum 25% public-float threshold as at 31 August 2026.\nEquity Incentive Schemes  \n• Post-IPO Share Award Scheme (adopted 16 November 2022) recorded no share issuances or treasury transfers in August.  \n• The scheme’s current mandate allows up to 2.40 million shares to be issued upon vesting; historical grants comprise 435,000 shares in June 2025 and 514,068 shares in July 2026.\nRegulatory Confirmation  \n• The filing attests that any past share issuances have been duly authorised, funds received, and all Hong Kong listing rule conditions satisfied.\nOverall, VISEN PHARMA-B maintained a static share capital base in August 2026 with sufficient public float, signalling capital stability ahead of future vesting events under its share award programme.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171112454","isCrawlerRequest":true}